Biohaven Pharmaceutical Holding Company Stock News

Paul Tudor Jones is one of the most respected names in the hedge fund industry.

NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

"We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.

Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.

Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven th

The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.

The "new" Biohaven is enjoying plenty of attention from investors.

Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.

The "old" Biohaven is gone, leaving the "new" Biohaven to rise.

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY ) to develop and commercialize taldefgrobep alfa. Taldefgrobep, a Phase 3-ready anti-myostatin adnectin, is the third development asset licensed to Biohaven from Bristol Myers Squibb. The Company will initiate the taldefgrobep Phase 3 trial for Spinal Muscular Atrophy (SMA) in 2022. Bristol Myers Squibb will be eligible for regulatory approval milestone … Full story available on Benzinga.com

Biohaven Pharmaceutical (BHVN) and Pfizer (PFE) a committee of the European Medicines Agency ((EMA)) recommended the approval of 75 mg dose of rimegepant for the acute treatment…